Q&A: Vectura's Leaders Explain Synergies And Priorities For Merged Company
Executive Summary
Vectura's CEO James Ward-Lilley and incoming CFO from Skyepharma, Andrew Derodra, sat down with Scrip and explained where they see the excitement, synchronization and R&D fusion for the larger company.
You may also be interested in...
Sterna Sitting Pretty As Inflammatory Pipeline Shows Promise
In an interview with Scrip, Sterna Biologicals CEO Christian Pangratz says that the small German company has a number of options available to advance its Phase II projects in asthma, COPD, ulcerative colitis and atopic dermatitis.
Vectura CFO Sanguine Despite Flutiform Phase III COPD Trial Miss
Respiratory specialist Vectura has shrugged off disappointing Phase III results of Flutiform in COPD that could preclude the therapy’s use in that indication, saying that all hope is not yet lost and that the impact will be marginal in any case given Flutiform’s rising sales in treating asthma.
Coming Of Age: Pharma’s Influencer Marketing Matures
Influencer marketing has emerged as a potent tool for many industries and is a sector set to be worth $22bn in its own right by 2025.